trending Market Intelligence /marketintelligence/en/news-insights/trending/WY6gFsQikWk4BG6ArfepQA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cassiopea's Winlevi helps improve acne in late-stage study

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Cassiopea's Winlevi helps improve acne in late-stage study

Cassiopea SpA said 57% of acne patients had at least a two-step improvement resulting in either clear or almost clear faces after 52 weeks of treatment with Winlevi during a late-stage study.

The phase 3 trial, named Study 27, enrolled 609 patients who had previously completed 12 weeks of treatment of either Winlevi or placebo in preceding trials. The patients were treated with Winlevi for an additional nine months. Of the participants enrolled in the study, 416 completed treatment for at least 26 weeks and 119 completed 52 weeks of treatment.

The Investigator General Assessment, or IGA, was used to measure the severity of the acne, with an IGA score of zero being clear skin and a score of one meaning almost clear skin. The study also recorded a two-step improvement on the trunk, resulting in a zero or one IGA score for 62% of the participants at 52 weeks of treatment. No drug-related adverse events were reported during the study.

Winlevi, or clascoterone, is a new topical anti-androgen treatment which works on hormones that can lead to skin lesions.

CEO Diana Harbort said these results complete the data set necessary to file a new drug application for Winlevi.